JNJ-55308942 NEW
| Price | $70 | $172 | $278 |
| Package | 1mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: JNJ-55308942 | CAS No.: 2166558-11-6 |
| Purity: 100% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | JNJ-55308942 |
| Description | JNJ-55308942 is a selective and brain-penetrant antagonist of P2X7 functional with IC50s of 10 and 15 nM and Kis of 7.1 and 2.9 nM for hP2X7 and rP2X7, respectively. |
| In vitro | JNJ-55308942 shows pKis of 8.1and 8.5 for recombinant hP2X7 and rP2X7. JNJ-55308942 attenuates IL-1β release in a concentration-dependent manner in human blood and in mouse blood and microglia[2]. |
| In vivo | JNJ-55308942 (5 mg/kg; p.o.) shows the F of 81%, Vss of 1.7 L/kg, CL of 1.7 L/kg, Cmax of 3.7 mL min/kg, and AUC of 1747 ng/mL[1]. In male C57/BL6J mice, JNJ-55308942 (30?mg/kg; p.o.) significantly attenuates the effect of LPS on FSC, CD45 surface expression, and CD11b surface expression. In a model of Bacillus Calmette-Guerin-induced depression, JNJ-55308942 (30?mg/kg; orally) reverses the BCG-induced deficits of sucrose preference and social interaction (ED50 = 0.07?mg/kg). The P2X7 antagonist (3?mg/kg, orally) blocks Bz-ATP-induced brain IL-1β release in conscious rats[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 90 mg/mL (211.6 mM), Sonication is recommended. |
| Keywords | JNJ 55308942 | JNJ-55308942 | JNJ55308942 |
| Inhibitors Related | Opiranserin hydrochloride | Aurintricarboxylic acid | (E/Z)-Sivopixant | PSB-12062 | ATP disodium salt | Oxatomide | JNJ-42253432 | Ivermectin | Lappaconitine | CTP disodium dihydrate | AF-353 | Brilliant blue G-250 |
| Related Compound Libraries | Bioactive Compound Library | Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $2180.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $459.00/1mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-28 | |
| $1.00/1g |
VIP1Y
|
Apeloa production Co.,Limited
|
2024-06-19 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY